Health
Antibody improves progression-free survival in patients with advanced prostate cancer – News-Medical.Net
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer.
Reviewed by Emily Henderson, B.Sc.Sep 29 2020
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasized, castration-resistant prostate cancer.
This is the finding of the long-term analyses of an international phase 3 clinical trial, recently published in the leading journal “European Urology”. The study showed that overall survival was 2 – 3 times higher than in the placebo arm.
Ipilimumab is a humanized monoclonal IgG1 antibody that is…
-
General11 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News20 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
Noosa News18 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime
-
General13 hours agoPerth man charged after investigation into organised crime and tobacco store attacks